Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial

Asher A Chanan Khan, Kena C. Miller, Laurie Musial, Swaminathan Padmanabhan, Jihnhee Yu, Sikander Ailawadhi, Taimur Sher, Alice Mohr, Zale P. Bernstein, Maurice Barcos, Mehul Patel, Dan Iancu, Kelvin Lee, Myron S. Czuczman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma regimens are often poorly tolerated. Therefore, in a phase II clinical trial we investigated the efficacy of a steroid-free combination including bortezomib, pegylated liposomal doxorubicin and thalidomide (VDT regimen). Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen. Patient had a median of five prior therapies and 65.2% were refractory to their last regimen. The overall response rates were 55.5% and 22%, respectively. The median progression free survival was 10.9 months (95% CI: 7.3-15.8) and the median overall survival was 15.7 months (95% CI: 9.1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.

Original languageEnglish (US)
Pages (from-to)1096-1101
Number of pages6
JournalLeukemia and Lymphoma
Volume50
Issue number7
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Thalidomide
Multiple Myeloma
Steroids
Plasma Cells
Dexamethasone
Disease-Free Survival
Fatigue
Survival
liposomal doxorubicin
Bortezomib
Neoplasms
Therapeutics

Keywords

  • Bortezomib
  • Doxil
  • Multiple myeloma
  • Non-steroidal
  • Relapsed/refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma : Results of a phase II clinical trial. / Chanan Khan, Asher A; Miller, Kena C.; Musial, Laurie; Padmanabhan, Swaminathan; Yu, Jihnhee; Ailawadhi, Sikander; Sher, Taimur; Mohr, Alice; Bernstein, Zale P.; Barcos, Maurice; Patel, Mehul; Iancu, Dan; Lee, Kelvin; Czuczman, Myron S.

In: Leukemia and Lymphoma, Vol. 50, No. 7, 2009, p. 1096-1101.

Research output: Contribution to journalArticle

Chanan Khan, Asher A ; Miller, Kena C. ; Musial, Laurie ; Padmanabhan, Swaminathan ; Yu, Jihnhee ; Ailawadhi, Sikander ; Sher, Taimur ; Mohr, Alice ; Bernstein, Zale P. ; Barcos, Maurice ; Patel, Mehul ; Iancu, Dan ; Lee, Kelvin ; Czuczman, Myron S. / Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma : Results of a phase II clinical trial. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 7. pp. 1096-1101.
@article{aa0135d2032643a094d731fabc5eb8ca,
title = "Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial",
abstract = "Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma regimens are often poorly tolerated. Therefore, in a phase II clinical trial we investigated the efficacy of a steroid-free combination including bortezomib, pegylated liposomal doxorubicin and thalidomide (VDT regimen). Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen. Patient had a median of five prior therapies and 65.2{\%} were refractory to their last regimen. The overall response rates were 55.5{\%} and 22{\%}, respectively. The median progression free survival was 10.9 months (95{\%} CI: 7.3-15.8) and the median overall survival was 15.7 months (95{\%} CI: 9.1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.",
keywords = "Bortezomib, Doxil, Multiple myeloma, Non-steroidal, Relapsed/refractory",
author = "{Chanan Khan}, {Asher A} and Miller, {Kena C.} and Laurie Musial and Swaminathan Padmanabhan and Jihnhee Yu and Sikander Ailawadhi and Taimur Sher and Alice Mohr and Bernstein, {Zale P.} and Maurice Barcos and Mehul Patel and Dan Iancu and Kelvin Lee and Czuczman, {Myron S.}",
year = "2009",
doi = "10.1080/10428190902912460",
language = "English (US)",
volume = "50",
pages = "1096--1101",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma

T2 - Results of a phase II clinical trial

AU - Chanan Khan, Asher A

AU - Miller, Kena C.

AU - Musial, Laurie

AU - Padmanabhan, Swaminathan

AU - Yu, Jihnhee

AU - Ailawadhi, Sikander

AU - Sher, Taimur

AU - Mohr, Alice

AU - Bernstein, Zale P.

AU - Barcos, Maurice

AU - Patel, Mehul

AU - Iancu, Dan

AU - Lee, Kelvin

AU - Czuczman, Myron S.

PY - 2009

Y1 - 2009

N2 - Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma regimens are often poorly tolerated. Therefore, in a phase II clinical trial we investigated the efficacy of a steroid-free combination including bortezomib, pegylated liposomal doxorubicin and thalidomide (VDT regimen). Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen. Patient had a median of five prior therapies and 65.2% were refractory to their last regimen. The overall response rates were 55.5% and 22%, respectively. The median progression free survival was 10.9 months (95% CI: 7.3-15.8) and the median overall survival was 15.7 months (95% CI: 9.1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.

AB - Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma regimens are often poorly tolerated. Therefore, in a phase II clinical trial we investigated the efficacy of a steroid-free combination including bortezomib, pegylated liposomal doxorubicin and thalidomide (VDT regimen). Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen. Patient had a median of five prior therapies and 65.2% were refractory to their last regimen. The overall response rates were 55.5% and 22%, respectively. The median progression free survival was 10.9 months (95% CI: 7.3-15.8) and the median overall survival was 15.7 months (95% CI: 9.1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.

KW - Bortezomib

KW - Doxil

KW - Multiple myeloma

KW - Non-steroidal

KW - Relapsed/refractory

UR - http://www.scopus.com/inward/record.url?scp=68449088226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449088226&partnerID=8YFLogxK

U2 - 10.1080/10428190902912460

DO - 10.1080/10428190902912460

M3 - Article

C2 - 19479618

AN - SCOPUS:68449088226

VL - 50

SP - 1096

EP - 1101

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -